Holen Sie sich die Stockscreener-App
15.10
1.55%
0.23
Handel nachbörslich:
15.10
Schlusskurs vom Vortag:
$14.87
Offen:
$14.77
24-Stunden-Volumen:
266.22K
Relative Volume:
1.08
Marktkapitalisierung:
$673.00M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
-16.97
EPS:
-0.89
Netto-Cashflow:
$-27.23M
1W Leistung:
+2.44%
1M Leistung:
+6.64%
6M Leistung:
-11.95%
1J Leistung:
+176.05%
1-Tages-Spanne:
$14.77
$15.22
1-Wochen-Bereich:
$14.19
$15.22
52-Wochen-Spanne:
$4.69
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Firmenname
Y Mabs Therapeutics Inc
Sektor
Branche
Telefon
212-847-9841
Adresse
230 PARK AVENUE, NEW YORK, NY
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Eingeleitet | Truist | Buy |
| 2023-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-04-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-27 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-10-31 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-03 | Fortgesetzt | Guggenheim | Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-05-01 | Eingeleitet | Janney | Buy |
| 2020-04-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Eingeleitet | Wedbush | Outperform |
| 2019-04-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-10-16 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
(YMAB) Trading Advice - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com
Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN
Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World
Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Objective long/short (YMAB) Report - Stock Traders Daily
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times
Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail
13,566 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by SG Americas Securities LLC - Defense World
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers (NASDAQ:YMAB) - Seeking Alpha
AQR Capital Management LLC Makes New Investment in TreeHouse Foods, Inc. (NYSE:THS) - Defense World
Cubist Systematic Strategies LLC Has $80,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Cubist Systematic Strategies LLC Takes Position in Seer, Inc. (NASDAQ:SEER) - Defense World
Summit Materials, Inc. (NYSE:SUM) Shares Bought by SG Americas Securities LLC - Defense World
Pediatric Oncology Drugs Market Size, Share, Growth Insights - openPR
(YMAB) On The My Stocks Page - Stock Traders Daily
Millennium Management LLC Boosts Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.7%Still a Buy? - MarketBeat
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Cubist Systematic Strategies LLC Sells 71,189 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Squarepoint Ops LLC Acquires 74,452 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Squarepoint Ops LLC Has $1.53 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Long Term Trading Analysis for (YMAB) - Stock Traders Daily
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 6.1%Here's What Happened - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.1% - Defense World
Point72 Asset Management L.P. Sells 1,168,155 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 6.5% - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.14 Average PT from Analysts - MarketBeat
Y-mAbs to Participate in Upcoming Investor Conferences in October - The Manila Times
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces pivotal year - Investing.com
Radiotheranostics Revolution: What to Expect from the 2024 Global Market As Discussed In New Market Researc... - WhaTech
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
Jamf (NASDAQ:JAMF) Shares Gap Down to $18.70 - MarketBeat
Needham maintains Buy rating on Jamf shares with no price target change - Investing.com India
Jamf (NASDAQ:JAMF) Earns “Market Outperform” Rating from JMP Securities - Defense World
Jamf's (JAMF) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
272 Capital LP Acquires 44,486 Shares of Jamf Holding Corp. (NASDAQ:JAMF) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - MarketBeat
Stock Surge: Y-Mabs Therapeutics Inc (YMAB) Closes at 13.73, Marking a -1.93 Increase/Decrease - The Dwinnex
Examining the Potential Price Growth of Jamf Holding Corp (JAMF) - Knox Daily
How To Trade (YMAB) - Stock Traders Daily
Nothing is Better Than Y-Mabs Therapeutics Inc (YMAB) stock at the moment - SETE News
Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Y Mabs Therapeutics Inc-Aktie (YMAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 13 '24 |
Sale |
13.47 |
65,000 |
875,550 |
97,681 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 16 '24 |
Sale |
12.97 |
30,000 |
389,100 |
67,681 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):